: Moderna stock rallies 5% after respiratory virus vaccine trial meets endpoints


Moderna Inc. MRNA, -0.68% shares rallied in the extended session Tuesday after the biotech drug company said results from a late-stage clinical trial for its respiratory virus vaccine met endpoints, and that it will submit for Food and Drug Administration approval by mid-2023. Moderna shares surged as much as 5% after hours, following a 0.7% decline to close the regular session at $190.69. The company said data from a Phase 3 clinical trial of its mRNA-1345 vaccine candidate showed an efficacy of 83.7% against respiratory syncytial virus in older adults. At Tuesday’s close, Moderna shares were down 6.9% over the past 12 months, versus a 14.1% decline on the S&P 500 index SPX, -0.20%.

This article was originally published by Marketwatch.com. Read the original article here.

Previous articleThe Wall Street Journal: Supreme Court asks U.S. government to weigh in on Apple patent dispute
Next articleDow ends down nearly 400 points as Goldman Sachs stock weighs


Please enter your comment!
Please enter your name here